Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hL243-SN-38
- Development stage
- Preclinical
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
hL243-SN-38 is an investigational antibody-drug conjugate (ADC) consisting of the humanized anti-HLA-DR monoclonal antibody hL243 (IgG4) covalently linked to the cytotoxic agent SN-38, the active metabolite of irinotecan and a potent topoisomerase I inhibitor. The ADC is designed to target HLA-DR-expressing hematological malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL), by delivering SN-38 directly to cancer cells, thereby sparing normal tissues. Preclinical studies have shown that hL243-SN-38 results in a significant survival advantage over the parent antibody and other control treatments in xenograft models, with minimal toxicity observed in vivo. The drug-to-antibody ratio (DAR) is typically in the range of 6.1 to 6.6[2][8].
- Other names
- hL243-SN-38hL-243-SN-38hL 243-SN-38IMMU-140IMMU140IMMU 140
02
Targets
TOP1 (DNA Topoisomerase I)HLA-DR (Human leukocyte antigen DR)
Beyond the preview
Go deeper on hL243-SN-38.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hL243-SN-38.